Recruiting
Phase 2

Zanubrutinib and Venetoclax in CLL (ZANU-VEN)

Sponsor:

Dana-Farber Cancer Institute

Code:

NCT05168930

Conditions

Chronic Lymphocytic Leukemia (CLL)

Small Lymphocytic Lymphoma (SLL)

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Venetoclax

Zanubrutinib

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information